See the DrugPatentWatch profile for keytruda

Keytruda, a drug manufactured by Merck & Co., was first approved by the Food and Drug Administration (FDA) for the treatment of metastatic melanoma [1]. This approval was granted in September 2014 [1]. Keytruda, also known as pembrolizumab, is a type of immunotherapy that helps the body's immune system fight cancer [1].

Metastatic melanoma is a type of skin cancer that has spread to other parts of the body [2]. It is a serious and life-threatening condition, and the approval of Keytruda for its treatment was a significant milestone in the field of oncology [1].

Since its initial approval, Keytruda has been approved for the treatment of several other types of cancer, including non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high (MSI-H) cancer [1].

Sources:

* [1] DrugPatentWatch.com. Keytruda (pembrolizumab). <https://www.drugpatentwatch.com/drugs/keytruda>.
* [2] American Cancer Society. What is melanoma skin cancer? <https://www.cancer.org/cancer/melanoma-skin-cancer/about/what-is-melanoma.html>.